Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

<b>:</b><b> </b>Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic opti...

Full description

Bibliographic Details
Main Authors: Carlo Buonerba, Pasquale Dolce, Simona Iaccarino, Luca Scafuri, Antonio Verde, Ferdinando Costabile, Martina Pagliuca, Rocco Morra, Vittorio Riccio, Dario Ribera, Pietro De Placido, Valeria Romeo, Felice Crocetto, Nicola Longo, Ciro Imbimbo, Sabino De Placido, Giuseppe Di Lorenzo
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
renal cell carcinoma
sarcomatoid
immune checkpoint inhibitors
pd-1
pd-l1
Online Access:https://www.mdpi.com/2072-6694/12/2/408

Internet

https://www.mdpi.com/2072-6694/12/2/408

Similar Items